Genomic code for Sox2 binding uncovers its regulatory role in Six3 activation in the forebrain  by Lee, Bumwhee et al.
Developmental Biology 381 (2013) 491–501Contents lists available at ScienceDirectDevelopmental Biology0012-16
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/developmentalbiologyGenomes and Developmental ControlGenomic code for Sox2 binding uncovers its regulatory role in Six3
activation in the forebrain
Bumwhee Lee a, Hobeom Song a, Karine Rizzoti b, Youngsook Son a, Jaeseung Yoon a,
Kwanghee Baek a, Yongsu Jeong a,n
a Department of Genetic Engineering, College of Life Sciences and Graduate School of Biotechnology, Kyung Hee University, Yongin-si 446-701, Republic of
Korea
b Division of Stem Cell Biology and Developmental Genetics, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UKa r t i c l e i n f o
Article history:
Received 7 April 2013
Received in revised form
9 June 2013
Accepted 12 June 2013
Available online 19 June 2013
Keywords:
Sox2
Six3
Forebrain
ChIP Display
Mouse06/$ - see front matter & 2013 Elsevier Inc. A
x.doi.org/10.1016/j.ydbio.2013.06.016
esponding author. Fax: +82 31 203 8127.
ail address: yongsu@khu.ac.kr (Y. Jeong).a b s t r a c t
The SRY-related HMG box transcription factor Sox2 plays critical roles throughout embryogenesis.
Haploinsufﬁciency for SOX2 results in human developmental defects including anophthalmia, micro-
phthalmia and septo-optic dysplasia, a congenital forebrain defect. To understand how Sox2 plays a role
in neurogenesis, we combined genomic and in vivo transgenic approaches to characterize genomic
regions occupied by Sox2 in the developing forebrain. Six3, a homeobox gene associated with
holoprosencephaly, a forebrain midline defect, was identiﬁed as a Sox2 transcriptional target. This study
shows that Sox2 directly regulates a previously unidentiﬁed long-range forebrain enhancer to activate
Six3 expression in the rostral diencephalon. Further biochemical and genetic evidences indicated a direct
regulatory link between Sox2 and Six3 during forebrain development, providing a better understanding
of a common molecular mechanism underlying these forebrain defects.
& 2013 Elsevier Inc. All rights reserved.Introduction
Sox2 is a member of the Sox family of transcription factors that
contain the SRY-related high mobility group (HMG) box. On the
basis of HMG box homology Sox2 belongs to the SoxB1 subfamily
and is best known for its role in the establishment and main-
tenance of embryonic stem (ES) cells (Bowles et al., 2000; Pevny
and Lovell-Badge, 1997). Recently Sox2 has been shown to be a key
factor in pluripotency induction in various somatic cell types
(Takahashi and Yamanaka, 2006; Yamanaka, 2012). Sox2 also
performs a wide range of functions during embryo development.
After ectoderm formation, Sox2 expression is largely restricted to
the neuroectodermal cells and plays a critical role in early central
nervous system development (Pevny and Placzek, 2005). Studies
in chick and Xenopus embryos showed that Sox2 is needed to keep
neural progenitors undifferentiated by repressing the activity of
proneural genes (Graham et al., 2003; Kishi et al., 2000). Sox2
heterozygous mouse embryos did not manifest overt abnormal-
ities, although one third of the embryos had anterior pituitary
defects (Kelberman et al., 2006). Hypomorphic Sox2 embryos, in
which the protein level is decreased to 15%–40% of wild type,
showed that Sox2 is a dose-dependent key regulator of brain andll rights reserved.eye development (Ferri et al., 2004; Langer et al.,2012). Reduced
Sox2 dosage resulted in abnormal hypothalamic patterning and
disrupted the morphogenesis of the optic cup, causing variable
microphthalmia (Langer et al.,2012; Taranova et al.,2006). More-
over, complete ablation of Sox2 in the developing retina led to a
failure to maintain retinal neural progenitors in an undifferen-
tiated state and resulted in severe microphthalmia (Taranova et al.,
2006). The neural retina and hypothalamus are more sensitive
than other regions of the neuroepithelium to Sox2 dosage, likely
because the other SoxB1 members, Sox1 and Sox3, are not
expressed in the neural retina, and Sox1 is excluded from the
ventral diencephalon.
Normal dosage of SOX2 is also critical for human development.
SOX2 haploinsufﬁciency has been associated with anophthalmia,
microphthalmia, and septo-optic dysplasia (SOD) which is a
congenital brain malformation with pituitary, optic nerve, and
midline forebrain defects (Kelberman et al., 2006; Fantes et al.,
2003; Kelberman and Dattani, 2007; Williamson et al., 2006).
Despite the recognition of critical roles of Sox2 in central nervous
system (CNS) development, little is known about mechanisms of
how Sox2 deﬁciency leads to different outcomes in dose- and
context- dependent manners. This is partly due to the limited
number of known Sox2 targets during the progress of CNS
development. Previous analyses of Sox2 targets have primarily
been performed in ES cells or ES-derived neural progenitor cells
(Bergsland et al., 2011; Chen et al., 2008; Peterson et al., 2012).
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developing CNS regions, but context-speciﬁc targets remain to
be determined. Several independent investigations indicated that
Sox2 is a direct regulator of Shh and Six6 in the hypothalamus, and
of Pax6, Rax, and the delta-crystallin gene in the eye (Danno et al.,
2008; Donner et al., 2007; Kamachi et al., 2001; Lee et al.,2012;
Zhao et al., 2012).
To provide a better understanding of the gene regulatory
network in the CNS we identiﬁed additional genes expressed in
the developing forebrains that are activated by Sox2. By genome-
scale location analysis and in vivo veriﬁcation, novel Sox2 tran-
scriptional targets were identiﬁed. Interestingly, we revealed a
Sox2-bound genomic region that functions as a long-range acting
forebrain enhancer of Six3, which is a critical regulator of forebrain
development and one of the major causes of holoprosencephaly
(HPE). Further biochemical and genetic evidences indicated that
Sox2 directly regulates this remote Six3 forebrain enhancer. Given
our data, and that recently reported by other (Beccari et al., 2012),
we propose that Sox2-dependent Six3 activation is critical for
forebrain development.Materials and methods
ChIP Display
Chromatin immunoprecipitation (ChIP) was performed using
the ChIP assay kit (Millipore) following the manufacturer's instruc-
tion. Display was performed essentially as previously described
(Barski and Frenkel, 2004). E10.5 mouse embryos were harvested
in DMEM containing 10% fetal bovine serum and ﬁxed with 1%
formaldehyde for 20 min with shaking. After a 10 min incubation
with 10 mM glycine, forebrain tissues were dissected and dis-
rupted in lysis buffer (provided in the kit) by passing through 30 G
needles, then nuclei were pelleted and resuspended in nuclei lysis
buffer (provided in the kit). Chromatin was sonicated and incu-
bated overnight with anti-Sox2 (Abcam, ab15830) or IgG (SantaFig. 1. ChIP-Display coupled with functional in vivo assay to identify targets of Sox2 in the d
immunoprecipitated with anti-Sox2 antibody. After dephosphorylation with rAPid alkaline
the chromatin DNAs were digested with AvaII to scatter non-speciﬁc DNAs, ligated to linke
independent ChIPs were puriﬁed and re-ampliﬁed by PCR. The resulting PCR products w
sequenced for identiﬁcation. Novel SBRs were cloned into a reporter construct and assayCruz, sc2025), followed by incubation with protein A/G agarose
beads. After washing and elution with buffers (provided in the kit),
DNA was puriﬁed and subjected to Display. The immunoprecipi-
tated DNA was treated with rAPid alkaline phosphatase (Roche),
digested with AvaII, and ligated to linkers (sense, 5'–
TTCGCGGCCGCAC-3'; antisense, 5'–GWCGTGCGGCCGCGAA-3').
After puriﬁcation with a MinElute kit (Qiagen), the DNA was
subjected to PCR ampliﬁcation using nested primers (5'–
CGGCCGCACGWCCN-3'). After the resulting PCR products were
resolved on 6% PAGE, DNA from each band was puriﬁed with
QIAEX II columns (Qiagen) and reampliﬁed by PCR. The resulting
DNAs were digested with HinfI or MspI and resolved on 2% agarose
gel electrophoresis. Bands of interest were excised and the DNA
was puriﬁed with GeneClean III kit (BIO101) for sequencing.
Quantitative PCR was performed with a QuantiTect SYBR Green
PCR kit (Qiagen) using the primers listed in Supplementary Text 1.
Generation of reporter constructs and production of transgenic mice
SBR sequences assayed were cloned into the NotI restriction
site of a reporter vector containing the beta-globin minimal
promoter, lacZcDNA, and SV40 large T antigen poly(A) site. Tran-
sient transgenic embryos or mouse lines were generated by
pronuclear injection into fertilized eggs derived from FVBN strains.
The list of primer sequences used for PCR ampliﬁcation is shown
in Supplementary Text 1. To test the requirement of each Sox2
binding site in SBR25, mutations designed to disrupt DNA binding
at the recognition sequences were constructed by a three-
component assembly ligation of two PCR product and reporter
vector. Each primer sequence is shown in Supplementary Text 1.
Whole-mount β-galactosidase staining and whole-mount in situ
hybridization
The β-galactosidase activity was measured using X-gal (Roche)
as substrate (Lee et al., 2012). Representative embryos were ﬁxedeveloping forebrain: Chromatin DNAs were isolated from E10.5 mouse forebrains and
phosphatase to prevent ligation of linkers to the DNA ends generated by sonication,
rs, and subjected to PCR using nested primers. DNAs from bands reproduced in three
ere digested with HinfI and MspI, resolved on 2% agarose gel electrophoresis and
ed for enhancer activity in transient transgenic mouse embryos.
Fig. 2. Sox2 bound regions act as functional regulatory enhancers during embryogenesis: Transient transgenic reporter assays of Sox2-bound regions (SBRs) performed in E10.5
embryos. Shown at the top of each panel shown is Multiz Alignment of SBRs among vertebrate species (http://genome.ucsc.edu). Numbers of embryos exhibiting
reproducible reporter activity over total number of transgenic embryos are indicated in Supplementary Table 1. hg19, human; galGal4, chicken; xenTro3, frog; fr3, fugu;
danRer7, zebraﬁsh.
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temperature medium (OCT) and sectioned at 20 μm on a cryo-
stat. Whole-mount RNA in situ hybridization was carried out
using digoxygenin-UTP-labeled riboprobes against Six3, Sox2,
and Sox3 according to a previously described protocol (Jeong
et al., 2006). Some of the stained embryos were photographed
after clearing in a 1:1 benzyl alcohol/benzyl benzoate solution
and rehydrated, soaked in 30% sucrose, frozen in OCT, and
cryosectioned at 20 μm.
Electromobility shift assays (EMSA)
CHO cells were transfected with pcDNA3-Flag or pcDNA3-Flag-
Sox2 plasmids using Lipofectamine 2000 transfection reagent
(Invitrogen). After 48 h, whole -cell lysates were prepared in a
buffer containing 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Triton
X-100, and 0.5% sodium deoxycholate. EMSA was performed as
described (Jeong et al., 2006, 2008). The nucleotide sequences of
probe and competitors are as follows:
SBR25(S1), 5'–TTATATAAATGGCTTTGTAAAGAAAACTATAA-3'
SBR25(ΔS1), 5'–TTATATAAATGGGCCCGCGAAGAAAACTATAA -3'
SBR25(S2), 5'–CCAGCACAAACTCAACAATACGCACAGCCTAG -3'
SBR25(ΔS2), 5'-CCAGCACAAACTGCCGCCGCCGCACAGCCTAG-3'
Fbx15: 5'–GGAGATGTGCTTTATCATAACAATGGAATTCCTAGGGGCT-3'
Transient transfection and dual reporter assay
CHO cells seeded at 70% conﬂuency were transfected with
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions. Two μg of pcDNA3-Sox2 expression plasmid or empty
vector was mixed with 5 ng of pRL-TK vector (Promega) as an
internal control, and 1 μg of SBR25::lacZ, SBR25(ΔS1)::lacZ, or
SBR25(ΔS2)::lacZ reporter plasmid. Cells were harvested and lysed
48 h after transfection by adding 100 μl of lysis solution (Dual-
Light System; Applied Biosystems). β-galactosidase activity was
determined by Galacton-Plus substrate reaction, and normalized
to that produced by Renilla luciferase (Dual-Light System; Applied
Biosystems).Results
Genome-wide location of Sox2-bound regions in the developing
forebrain
To obtain better insight into the role of Sox2 in CNS develop-
ment, particularly forebrain development, in vivo Sox2 binding
sites throughout the mouse genome were identiﬁed by coupling
chromatin immunoprecipitation (ChIP)–Display with transgenic
mouse reporter assays (Fig. 1). Chromatin DNA immunoprecipi-
tated from E10.5 mouse forebrains by Sox2 antibody was depho-
sphorylated, digested, and ligated to linkers, followed by PCR
ampliﬁcation (Barski and Frenkel, 2004). To reduce non-speciﬁc
background fragments and the complexity of DNA resolved on a
polyacrylamide gel (PAGE), the ligated restriction fragments were
segregated into groups by 36 separate PCR reactions with 8 nested
primers (see Materials and Methods). Only bands reproduced in
three independent Sox2 ChIP lanes and in none of the IgG control
lanes were excised from the PAGE and reampliﬁed. The resulting
products were subjected to secondary digestion to further sepa-
rate any co-migrating bands as well as to verify, before sequencing,
that DNA fragments isolated from the three different lanes were
the same. Sequences from these digested subfragments were
aligned with the mouse genome using UCSC genome browser(http://genome.ucsc.edu). From these location analyses we identi-
ﬁed a total of 102 Sox2 bound regions (SBRs) (Supplementary
Table 1). From the list of SBRs, we randomly selected eight regions
and tested these by ChIP-QPCR. Signiﬁcant enrichment was
detected in all of the SBRs tested (n¼8/8; Supplementary Fig. 1),
validating the consistency of Sox2 occupied locations.
We next matched the SBRs to the nearest annotated transcrip-
tion units, and found several SBRs located from the known target
genes of Sox2 in the developing CNS, Nestin, Pax6, Shh, and Sox2
(Danno et al., 2008; Donner et al., 2007; Kamachi et al., 2001;
Tanaka et al., 2004; Zhao et al., 2012; Supplementary Table 1).
When comparing the SBRs with recent Sox2 binding data from ES
cells or their neural derivatives (Bergsland et al., 2011; Chen et al.,
2008; Peterson et al., 2012), we found that 63 SBRs did overlap
with ES cells-associated Sox2-bound regions, suggesting that a
signiﬁcant fraction of Sox2-bound regions were reused at later
developmental stages.
To identify forebrain-speciﬁc targets of Sox2, we focused on
SBRs that were not shared in ES cell or their neural derivatives. To
examine the functional relevance of these novel SBRs in vivo, we
cloned each sequence into a reporter construct containing beta-
globin minimal promoter, lacZ reporter and SV40 polyA, and
analyzed reporter expression in transient transgenic mouse
embryos (Supplementary Text 1). Of the 35 SBRs tested, 30
displayed highly speciﬁc and reproducible X-gal staining in the
developing embryonic tissues including the forebrain (Fig. 2;
Supplementary Table 1). Of these SBRs, 14 showed consistent
expression in the forebrain regions, 5 in the eye, 10 in the
craniofacial regions, and 11 in the branchial arch (Fig. 2; Supple-
mentary Table 1). These data suggest that the majority of these
novel SBRs can serve as functional regulatory enhancers, thus
validating the efﬁcacy of this strategy to identify Sox2 targets.
SBR25 is a Six3 forebrain enhancer
Prominent on the list of SBRs displaying enhancer function in
the forebrain is SBR25 which directs lacZ expression to the ventral
forebrain (Fig. 2) and is located between the nearest upstream
(4425 kb) genes, Camkmt (calmodulin-lysine N-methyltransfer-
ase), Prep1 (prolylendopeptidase-like), Slc3a1 (solute carrier
family3 a1), and Ppm1b (protein phosphatase 1B) and downstream
(4125 kb) genes, Six3 and Six2 (Fig. 3). Camkmt, Prepl, Slc3a1, and
Ppm1b are widely expressed in various tissues (Parvari et al.,
2005), Six2 is in non-neural derivatives of neural crest origins
(Oliver et al., 1995a), and Six3 is found in the ventral forebrain and
eye (Oliver et al., 1995b). Therefore, attention was directed to Six3
because of SRB25 tissue speciﬁcity. Six3, a member of the Six gene
family that has been identiﬁed as a vertebrate homolog of the
Drosophila sine oculis gene, plays crucial roles in the development
of brain and craniofacial structures. Six3−/− mouse embryos lack
anterior forebrain and exhibit severe craniofacial abnormalities
(Lagutin et al., 2003). In humans, SIX3 mutations have been
associated with HPE, a defect in anterior midline formation with
a spectrum of brain and craniofacial malformations (Wallis et al.,
1999). HPE phenotypes overlap in several features reported for the
Sox2 causative diseases, such as anophthalmia and SOD. Early Six3
expression is restricted to the anterior neural plate, and is later
predominantly detected in the ventral forebrain, eye, and rostral
non-neural tissues. Sox2 expression showed a broad distribution
along the CNS axis, but at the forebrain level, was far more
prominent in the ventral ﬂoor and dorsal roof (Fig. 4). Interest-
ingly, Six3 mRNA was embedded within the Sox2 expression
domain in the ventral forebrain (Fig. 4).
In all of 7 transient transgenic embryos carrying SBR25, X-gal
staining was detected in the ventral forebrain where Six3 is
normally expressed (Fig. 3). To examine the expression pattern
Fig. 3. Identiﬁcation of a Sox2-bound region as a Six3 forebrain enhancer: (Top) Genomic location of SBR25 (red). Close view of a 1-Mb genomic locus in band E4 of the mouse
chromosome 17. Genomic locations and organizations including exons, introns and 5' to3' direction of nearest upstream (Camkmt, Prepl, Slc3a1, Ppmlb) and downstream (Six3,
Six2) genes are shown in brown. (A–H) Time-course of Six3 (A–D) and SBR25::lacZ (E–H). At E8.5, Six3 expression is present in the eye ﬁeld (arrow) and ventral forebrain
(arrowhead) (A, A'), while SBR25 directed lacZ expression only in the ventral forebrain (arrowhead) albeit ectopic staining was occasionally detected (asterisk) (E, E'). At E9.5
–E12.5, Six3 expression is also detected in several brain compartments (B–D). X-gal staining driven by SBR25 is conﬁned to the anterior diencephalon and its derivative
hypothalamic region (F–H). (D, H) Heads were bisected sagitally along the midline prior to staining. Di, diencephalon; HY, hypothalamus; MB, midbrain; OP, olfactory
placode; OV, optic vesicle; RP, Rathke's pouch; rTH, rostral thalamus; SP, subpallium; PreT, pretectum; PT, prethalamus; Tel, telencephalon.
Fig. 4. Comparison of Six3 and SoxB1 expression in the ventral forebrain: (A–F) Whole-mount in situ hybridization for of Six3 (A, D), Sox2 (B, E) and Sox3 (C, F) showing
colocalization of Six3, Sox2 and Sox3 in the ventral forebrain. Six3 and Sox2 are also co-expressed in the optic vesicle and olfactory placode, while Sox3 expression is detected
in the olfactory placode at low levels and is down-regulated normally in the optic vesicle at E10.5. Dashed lines (A–C) indicate the planes of transverse sections (D–F) through
the forebrain at the level of the anterior hypothalamus.
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dent stable mouse lines carrying the transgene were generated. At
E8.5, Six3 is expressed in the most rostral border of the neural
plate including the ventral forebrain and eye ﬁeld (Fig. 3A, A')
(Oliver et al., 1995b). This unique pattern of Six3 expression in theventral forebrain and eye is maintained at later stages (Fig. 3B, C).
As distinct brain compartments emerge, in addition to the deri-
vatives of the forebrain and eye, Six3 expression is also detected in
other brain regions including prethalamus, rostral thalamus, pre-
tectum, and ventral midbrain (Fig. 3D). In all transgenic embryos
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expression was similarly observed in the ventral forebrain, but not
in the eye ﬁeld (Fig. 3E, E'). At later stages, X-gal staining was
present in the anterior diencephalon and its derivative hypotha-
lamus where Six3 is normally expressed (Fig. 3F, H), indicating that
the transgene faithfully recapitulates the expression pattern of
Six3 in the ventral forebrain. Therefore, we concluded that SBR25
functions as a regulatory enhancer to control Six3 transcription in
the ventral forebrain.
Six3 forebrain enhancer is functionally conserved
We further characterized this enhancer by assessing the activ-
ity of orthologous sequences from divergent organisms. Blat
searches using the UCSC genome browser (Multiz Alignments of
60 vertebrates) were performed to determine whether SBR25 is
evolutionarily conserved. These comparative sequence analyses
identiﬁed conserved sequences from 56 of 60 vertebrates that are
placed at various distances from the Six3 coding region (Fig. 5). We
cloned SBR25 sequences from human, chicken, and frog into the
reporter cassette and examined the enhancer activity in transgenic
mouse embryos. Strong lacZ expression in transgenic embryos
carrying human (n¼3/3), chicken (n¼10/10) and frog SBR25
(n¼3/5) sequences was detected in the ventral forebrain in a
manner similar to mouse SBR25 (Fig. 5C–E), indicating functional
conservation of the Six3 enhancer in these species. In contrast,
SBR25 from teleost ﬁshes differed signiﬁcantly from the other
vertebrates. Despite low conservation, we tested the enhancer
activity in transgenic mouse embryos. None of the embryos
carrying zebraﬁsh (n¼0/8) or medaka SBR25 (n¼0/7) showed
X-gal staining in the forebrain despite the presence of ectopicFig. 5. Functional conservation of Six3 forebrain enhancer: (A) Multiz alignment comparin
medaka and zebraﬁsh (UCSC genome browser, http://genome.uscs.edu). (B) Compariso
zebraﬁsh, and medaka. (C–G) SBR25 reporter activity derived from human (C; hg19 c
xenTro3 GL172661:1607059-1608352) zebraﬁsh (F; danRer7 chr13:9896009-9896990),X-gal staining (Fig. 5F, G). The medaka regulatory element has been
recently shown to control one of the two Six3 medaka homologs,
Six3.2 (Conte and Bovolenta, 2007), and was found to be located far
distant from SBR25. Transgenic mouse embryos carrying the
medaka sequences containing module G, H and I (n¼0/7) or mouse
counterpart (n¼0/7) failed to activate transgene expression in the
forebrain (Supplementary Fig. 2). Given that vertebrate Six3 dis-
plays similar features of expression, these results indicated pro-
found divergence of the regulatory mechanisms underlying the
pattern of Six3 activation.
Six3 forebrain enhancer activity is dependent on Sox2-binding sites
The ﬁnding that the Sox2-bound region functions as a Six3
regulatory element suggests that Sox2 may act upstream of Six3 in
the ventral forebrain. To address this question, we ﬁrst examined
whether Sox2 binding site is required for Six3 forebrain enhancer
activity. Because a variety of ChIP-associated genome-wide ana-
lyses do not pinpoint nucleotide sequences occupied by transcrip-
tion factors, we searched for Sox2 binding sites by scanning the
enhancer sequence using the rVISTA tool as well as by comparing
the consensus site [(A/T)(A/T)CAA(A/T)G] manually. This analysis
recognized four putative binding sites for Sox2 in the enhancer
that were highly conserved in human, mouse, chicken and frog,
but not in teleost ﬁshes (S1–S4 in Fig. 6). To address the in vivo
signiﬁcance of the candidate binding sites on forebrain transcrip-
tion, reporter constructs were generated harboring point muta-
tions in each of the core recognition sequences. Due to the nature
of random integration of transgenes into the genome, it is not
feasible to discriminate between the effects of transgene silencing
and mutation. Therefore, lacZ expression in variable ectopicg SBR25 sequences of human, dog, horse, opossum, chicken, frog, tetraodon, fugu,
n of the distance between SBR25 and the Six3 ﬁrst exon in human, chicken, frog,
hr2:45031501-45032719), chicken (D; galGal4 chr3:25080030-25080913), frog (E;
and medaka (G; oryLat2 chr15:15513062-15513890).
Fig. 6. Six3 forebrain enhancer activity is dependent on highly conserved Sox2 binding sites: A schematic of the reporter construct indicating the locations of the Sox2 binding
sites (S1–S4) in mouse SBR25 is shown at the top. Below are parts of alignments of SBR25 sequences frommouse, human, chicken, and frog. Conserved Sox2 binding sites are
shaded in yellow. (A–D) X-gal staining of transgenic embryos at E10.5 carrying reporter constructs with mutant DNA binding sites.
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show X-gal staining in any places were not used to account for the
effect of mutation. Transgenic embryos carrying the SBR25 with
the mutated S1 site failed to activate lacZ in the ventral forebrain
(n¼7/7; Fig. 6A). The effect of mutating the S2 site was also
dramatic as each of the transgenic embryos carrying the S2
mutation showed either a complete absence (n¼7/10) or very
weak patchy (n¼3/10) expression of lacZ in the ventral forebrain
(Fig. 6B). In contrast, point mutations in the S3 (n¼5/5) or S4 sites
(n¼7/10) had no consequences on transgene expression in the
ventral forebrain (Fig. 6C, D). These results demonstrated that the
Sox2 binding sites are critical for Six3 forebrain enhancer function.
Sox2 directly activates the Six3 forebrain enhancer
To further determine if the Sox2 protein directly regulates the
Six3 forebrain enhancer, we performed electromobility shift assays
to determine whether the binding sites S1 and S2 in the SBR25
could be bound by Sox2. CHO cell lysates transfected with Flag-
tagged Sox2 formed a speciﬁc complex when incubated with a
radiolabeled SBR25 (S1). This protein-DNA complex was super
shifted when exposed to anti-Flag antibody, but not control IgG
(Fig. 7A), indicating that the binding of Sox2 to the S1 site of SBR25
was direct. We also evaluated the afﬁnity of Sox2 for SBR25 (S1)
compared to the mutated site SBR25 (ΔS1) and a previously
identiﬁed binding site in the Fbx15 promoter. In the presence of
excess wild-type SBR25 (S1) or Fbx15-derived unlabeled compe-
titor, the majority of the radiolabeled SBR25 (S1) probe was
displaced from Sox2, whereas when excess SBR25 (ΔS1) unlabeled
competitor was introduced, marginal inhibitory effect was
observed (Fig. 7A, C). We obtained similar results when testing
the binding site S2 as the radiolabeled probe (Fig. 7B, D). We also
conﬁrmed Sox2 binding to SBR25 in vivo by ChIP-QPCR. SBR25 was
signiﬁcantly enriched in Sox2-bound chromatin, whereas a control
sequence, 3.5 kb downstream of SBR25, was not enriched in Sox2-
bound chromatin (Fig. 7E).Sox2 protein acts as a transcriptional activator in the nervous
system. To determine if Sox2 is able to stimulate SBR25 enhancer
activity, we carried out transient transfection assays in CHO cells
by using wild type and mutant SBR25::lacZ constructs. Cotransfec-
tion of SBR25::lacZ with pcDNA3-Sox2 led to marked elevation of
β-galactosidase activity (Fig. 7F). In contrast, SBR25::lacZ(ΔS1) and
SBR25::lacZ(ΔS2), but not SBR25::lacZ(ΔS3) or SBR25::lacZ(ΔS4),
showed signiﬁcantly reduced lacZ activity (Fig. 7F), and further-
more, combined mutation of S1 and S2 abrogated activation of
SBR25 enhancer (Fig. 7F). Taken together, these data demonstrated
that Sox2 is a direct regulator of Six3 forebrain enhancer. Previous
reports have shown the cooperation of Sox2 and other partner
factors such as Oct3/4, Brn2 and Pax6 that bind DNA in the vicinity
of the Sox2 site (Ambrosetti et al., 1997; Kamachi et al., 2001;
Kondoh and Kamachi, 2010; Tanaka et al., 2004). Thus, we
surveyed sequences around the Sox2 binding sites, S1 and S2, for
consensus sites recognized by these factors. However we did not
ﬁnd the potential binding sites. The identity of binding partners
for regulating the Six3 forebrain enhancer activity, therefore,
remains to be determined.
Six3 transcription in the ventral forebrain is down-regulated in SoxB1
mutants
We next determined whether Sox2 is required to regulate Six3
expression. Homozygous Sox2 knockout embryos do not form
epiblast and extraembryonic ectoderm properly and die soon after
implantation (Avilion et al., 2003). As Sox2+/− display abnormal
pituitary development (Kelberman et al., 2006), we examined the
expression pattern of Six3 in the heterozygotes. Compared to con-
trols, Six3 expression was similarly detected throughout the nervous
system (data not shown). The SoxB1 subfamily comprises Sox1, Sox2,
and Sox3 on the basis of phylogenetic analysis of HMG domains
(Bowles et al., 2000; Pevny and Lovell-Badge, 1997). Because Sox2
and Sox3 are widely co-expressed in the nervous system including
the ventral forebrain, share common transcriptional targets, and
Fig. 7. Sox2 binds directly to the Six3 forebrain enhancer: (A, B) EMSAs performed with CHO cell extracts transfected with pcDNA3-Flag (lane 1) or pcDNA3-Flag-Sox2 (lanes 2–
13) expression vectors and incubated with SBR25 (S1) (A) or SBR25 (S2) (B) -radiolabeled probes. Speciﬁc DNA-protein complexes were super shifted in the presence of anti-
Flag antibody (lane 4) but not nonspeciﬁc IgG (lane 5). (C, D) Graphical representation of the data in A and B. The relative intensities of the speciﬁc DNA-protein bands were
determined and plotted against competitor concentration. (*Po0.01, Student's t-test). (E) ChIP from embryos using anti-Sox2 or IgG. QPCR results from three independent
experiments indicate a signiﬁcant enrichment for SBR25 DNA in Sox2 chromatin versus IgG chromatin DNAs. (*Po0.01, Student's t-test). A negative control sequence, 3.5 kb
downstream of SBR25 was not enriched in Sox2 chromatin. (F) Sox2 stimulates SBR25 activity in vitro. CHO cells were cotransfected with pcDNA3-Sox2 expression DNA and
SBR25::lacZ, SBR25::lacZ(ΔS1), SBR25::lacZ(ΔS2), SBR25::lacZ(ΔS1,S2), SBR25::lacZ(ΔS3), SBR25::lacZ(ΔS4). pcDNA3-Sox2 activated wild-type SBR25::lacZ, compared to the
empty expression plasmid. This stimulation by Sox2 was reduced in cells expressing SBR25::lacZ(ΔS1) or SBR25::lacZ(ΔS2), but not SBR25::lacZ(ΔS3) or SBR25::lacZ(ΔS4).
Combined mutation of S1 and S2 abolished activation by Sox2. (*,**,*** Po0.01, Student's t-test). Each bar represents an average of three replicates. Each bar, s.d.
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Bylund et al., 2003; Kamachi et al., 1999;Wood and Episkopou, 1999),
they could act in a redundant fashion to control Six3 expression. We
thus examined the pattern of Six3 transcription in various SoxB1
compound mutant embryos. In Sox2+/−;Sox3+/− and Sox3y/− embryos,
the overall expression pattern of Six3 appeared normal compared to
wild type controls (Fig. 8B, C, F, and G). Remarkably, embryos with
the combined loss of three of four wild type alleles of Sox2 and Sox3
(Sox2+/−;Sox3y/−) showed a profound loss of Six3 transcription in the
ventral forebrain, while Six3 expression was similarly detected in
other regions including the eye and olfactory placode (Fig. 8D). Upon
sectioning Six3 expression was not detected in the ventral region of
the hypothalamus (Fig. 8H). In Sox2+/−;Sox3y/− mutants, Nkx2.1 and
Six6 expression were still detectable in the anterior diencephalon,indicating that loss of Six3 expression was not due to lack of
hypothalamic tissues (Supplementary Fig. 3; Lee et al., 2012). There-
fore, these results suggested that Sox2 and Sox3 function redun-
dantly to control Six3 transcription speciﬁcally in the ventral
forebrain.Discussion
In this study, we describe a functional genomic approach to the
analysis of Sox2 occupancy. By coupling ChIP-Display with trans-
genic reporter assays, we attempted to identify genomic locations
occupied by Sox2 protein in the developing forebrain. Despite less
high throughput compared to comprehensive ChIP-based location
Fig. 8. Six3 expression is disrupted in SoxB1 compound mutants: Whole-mount in situ hybridization for Six3 in wild-type (A, E) and SoxB1 mutant embryos (B–D, F–H) at E10.5.
Six3 transcription was similarly observed in Sox2+/−;Sox3+/− and Sox2+/+;Sox3y/− embryos (B, C, F, G). In contrast, compared to control, Sox2+/−;Sox3y/− embryos exhibited an
almost complete lack of Six3 expression in the ventral forebrain (D, H). Dashed lines (A–D) indicate the planes of transverse sections (E–H) through the forebrain at the level
of the anterior diencephalon.
B. Lee et al. / Developmental Biology 381 (2013) 491–501 499approaches such as ChIP-ChIP and ChIP-Seq, ChIP -Display proved
successful in identifying novel Sox2-bound targets that were
forebrain -speciﬁc. The strength of our approach relied on combin-
ing ChIP location analysis and functional in vivo assays, thereby
providing a direct connection between sequence and function.
Microarray expression proﬁling has been used to measure the
actual changes of gene expression under the control of a tran-
scription factor, but alone is unable to determine if the affected
genes are direct or indirect targets. Recently, the combined
analysis of gene expression proﬁling and ChIP based location is
emerging as an effective tool to speciﬁcally identify the list of
transcriptional targets (Zecchini and Mills, 2009). However it is
unlikely to be beneﬁcial in cases when nearest genes are closely
dispersed and show similar expression changes. Therefore, further
detailed experiments performed as with SBR25 are also required
to ascertain a direct link between transcription factor binding and
gene association.
Our analysis of Sox2 occupied regions shows that not all SBRs
are targeted by Sox2 in ES cell or their derivatives. In addition,
there are also considerable differences in target recognition of
Sox2 among ES and their derivative neural progenitor cells
(Bergsland et al., 2011; Chen et al., 2008; Peterson et al., 2012).
This indicated that transcriptional regulation by Sox2 is not ﬁxed,
but dynamically changes as developmental programs progress. For
example, two Sox2-bound regions SBR55 and SBR45 overlapped
with previously identiﬁed Shh regulatory elements, SBE2 and
SBE3, respectively (Supplementary Table 1; Jeong et al., 2006).
These elements, which regulate Shh transcription in distinct
regions of the forebrain, required direct Sox2 binding and activa-
tion (Favaro et al., 2009; Zhao et al., 2012), but were not Sox2-
targeted in ES or their derivatives. SBR59 corresponded to an
intron region that controls transcription of Nestin in the neural
tube (Supplementary Table 1). This Nestin neural enhancer con-
tained essential Sox binding sites (Tanaka et al., 2004), but was not
enriched with Sox2 ChIP in ES or their derivatives. However, it
remains to be determined how this shift in target recognition
occurs during the progression of developmental processes. Pre-
vious studies suggested that Sox2 functions are dependent on the
cooperation of partner factors that bind DNA near the Sox2
binding site (Kondoh and Kamachi, 2010). Recent genome-widestudies of partner factor binding, such as Pax6 and Chd7, revealed
transcriptional targets in embryonic neural tissues or neural stem
cells (Engelen et al., 2011, Xie et al., 2013). Chd7, a chromatin
remodeling ATPase, was shown to interact with Sox2 and co-
occupy half of the genomic regions bound by Sox2 in neural stem
cells. However, forebrain-speciﬁc SBRs were not targeted by these
cofactors. Therefore, other tissue -speciﬁc binding partners are
likely to participate in Sox2 regulation in the forebrain. Elucidating
the molecular mechanism by which its binding partner factors
cooperate with Sox2 to select target genes will uncover speciﬁc
roles of Sox2 in CNS development.
In determining genomic regions occupied by Sox2 we found a
novel interaction between Sox2 HMG protein and Six3 homeo-
protein during forebrain development. Six3 acts as a transcrip-
tional activator or repressor depending on cellular or tissue
context (Lagutin et al., 2003, Liu et al., 2006, Zhu et al., 2002).
Six3 was shown to protect the anterior neural ectoderm from the
posteriorising function of Wnt1 via repressing its transcription
(Lagutin et al., 2003). In contrast, Six3 was shown to positively
regulate Shh transcription in the ventral forebrain (Geng et al.,
2008;, Jeong et al., 2008) and Pax6 and Sox2 in the developing lens
(Liu et al., 2006). While progress has been made in deciphering the
functional role of Six3 as a transcription factor, little is known
about the mechanisms involved in activating Six3 transcription
during brain development. Six3 is expressed dynamically in
various regions of the brain and non-neural tissues from early
embryonic stages to adult. The restricted pattern of the reporter
activity of SBR25 in the anterior diencephalon suggested the
presence of multiple enhancers responsible for controlling Six3
transcription in other expression domains. A previous study using
medaka embryos identiﬁed cis-regulatory modules that function
as enhancers and silencers to control the entire Six3.2 distribution
(Conte and Bovolenta, 2007). In medaka embryos, the human
counterpart was found to drive a similar pattern of reporter
expression. In mouse embryos, however, the medaka enhancer,
its mouse counterpart, or teleost SBR25 sequences did not direct
reporter expression in any of the Six3 expression domains. Inter-
estingly, despite the presence of other medaka SoxB1 members,
knock-down of Sox2 alone was shown to result in loss of Six3.2
expression throughout the brain and eye (Beccari et al., 2012).
B. Lee et al. / Developmental Biology 381 (2013) 491–501500This observation was different from the case of mouse embryos in
that the combined loss of three of four wild type alleles of Sox2
and Sox3 failed to activate Six3 expression in the ventral forebrain.
Taken together, these results demonstrated that the regulatory
trans-acting function, but not the cis-acting structure may be
conserved among these vertebrate species. Similar regulatory
divergence reported in other instances, such as the regulatory
elements of Ret, Shh, and HoxC8 also showed that function or
structure is modiﬁed during the evolutionary process (Anand
et al., 2003; Epstein et al., 1999; Fisher et al., 2006; Müller et al.,
1999). Therefore, one can not necessarily predict regulatory func-
tion and architecture of an enhancer by extrapolation of the cis-
and trans-acting elements observed in one species.
Six3-causative human and mouse phenotypes overlap in sev-
eral features resulting from Sox2 mutations. Conditional ablation
of Six3 disrupted eye morphogenesis, causing anophthalmia and
microphthalmia (Liu et al., 2010). In these optic areas, Six3 is
required to activate Sox2 expression in the developing retina and
lens. Sox2 -deﬁciency also resulted in loss of retinal neural
progenitors as well as a failure of lens induction (Taranova et al.,
2006; Smith et al., 2009). In addition to the eye defects, Six3 and
Sox2 have been shown to play critical roles in rostral forebrain
development. Like humans, a 50% reduction of Six3 function in
mouse embryos, albeit with low phenotype penetrance and
genetic background dependence, gives rise to telencephalic mid-
line anomalies, including absence of septum pellucidum and
corpus callosum, which also manifest as defects in SOD (Geng
et al., 2008). Conditional removal of Six3 from neural progenitors
using Nestin-Cre leads to loss of the pituitary and disrupts normal
formation of hypothalamic nucleus (VanDunk et al., 2011). Analy-
sis of Six3+/−;Hesx1Cre/+ compound mutant embryos found pitui-
tary defects including dysmorphic and bifurcated Rathke's pouch,
while Hesx1Cre/+did not, revealing synergistic interaction of Six3
and another SOD-causative gene, Hesx1, in normal anterior pitui-
tary development (Gaston-Massuet et al., 2008). Similar to this
mutant, bifurcated anterior lobes have also been observed in
Sox2+/− and Sox3y/−embryos (Kelberman et al., 2006; Rizzoti
et al., 2004). Severe alterations in forebrain development were
also found in Sox2 hypomorphic mutants, Sox2F/F;Hesx1-Cre
embryos and Sox2F/F;Foxg1-Cre (Ferri et al., 2013; Jayakody et al.,
2012; Langer et al., 2012). Interestingly, these abnormalities
resulting from disruption of Six3 or Sox2 functions are likely to
be mediated partially by reduced Shh, another HPE-causative gene.
A portion of Six3+/ki and all of Six3+/ki;Shh+/−embryos failed to
express Shh in the ventral forebrain (Geng et al., 2008). Similarly,
Shh expression was also lost in the rostral diencephalon of Sox2+/−;
Sox3y/− compound mutant embryos and in the ventral telencepha-
lon of Sox2F/F;Foxg1-Cre embryos (Ferri et al., 2013; Zhao et al.,
2012). Interestingly, conditional ablation of Shh in the presumptive
hypothalamus resulted in SOD (Zhao et al., 2012). Moreover, the
distinct transcription factors, Six3 and SoxB1, were shown to be
direct upstream activators of Shh transcription in the ventral
forebrain (Geng et al., 2008; Jeong et al., 2008; Zhao et al., 2012).
As SoxB1 and Six3 are expressed in multiple CNS regions from early
stages, it will be important to determine to what extent each
spatiotemporal source of these transcription factors may be
involved during normal forebrain development and in the patho-
genesis of the forebrain defects.Acknowledgments
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